INCY

SELL

Incyte Corporation

Healthcare · Rank #61 · Analyzed Oct 18, 2026

$113.07

Current Price

$68.74

Intrinsic Value

low confidence

Upside/Downside

5/10

Score

5/5

Quality

Analysis Summary

Valuation Consensus1/3 methods agree

Quality Score5/5.0

Framework RatingSELL

Price vs Intrinsic ValueLow confidence — see rating

Fair Value Range

Low$19.41

Base (IV)$68.74

High$183.35

Entry Points

Conservative$13.59

Moderate$19.41

Aggressive$48.12

⚠️ Warnings

DCF/EPV diverge 4.2x — earnings power and cash flow disagree; fair value is low-confidence (blended conservatively)

Quality & Moat Breakdown

Return on Equity30.7% → 1.0/1.0

Debt LevelD/E 1 → 1.0/1.0

Revenue QualityGrowth 19.2%, margin Δ+22.8% → 1.0/1.0

Moat Strength4.5/5 → 1.0/1.0

Profit Margins27.7% → 1.0/1.0

Methodology

This analysis uses a unified valuation framework combining three methods, Discounted Cash Flow (3-scenario), Earnings Power Value, and Asset Valuation, with a quality scoring overlay. A stock needs 2/3 valuation methods to agree and a quality score ≥ 3.5/5 for a BUY rating.

Learn how this framework works →

This is a personal analysis tool, not financial advice. Do your own research before making investment decisions.